Positive results for Brainstorm’s ALS trial

As reported (here) previously, the stem cell treatment for ALS from Israel’s Brainstorm is doing well in trials.  The latest Phase 2 trial of Brainstorm’s autologous bone-marrow derived MSC-NTF cells (Nurown) in 48 patients at 3 US sites was effective and well tolerated.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *